| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRXN1 |
| Uniprot No | Q9BYN0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-137aa |
| 氨基酸序列 | MGLRAGGTLGRAGAGRGAPEGPGPSGGAQGGSIHSGRIAAVHNVPLSVLIRPLPSVLDPAKVQSLVDTIREDPDSVPPIDVLWIKGAQGGDYFYSFGGCHRYAAYQQLQRETIPAKLVQS |
| 预测分子量 | 19.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SRXN1重组蛋白的3篇代表性文献，包含标题、作者及摘要概述：
---
1. **标题**: *"Recombinant human sulfiredoxin (SRXN1) exhibits antioxidant activity by reducing peroxiredoxin substrates"*
**作者**: Jeong W, Bae SH, Toledano MB, et al.
**摘要**: 该研究报道了重组人源SRXN1蛋白的制备及其体外抗氧化功能。作者通过大肠杆菌表达系统纯化SRXN1.证明其能有效还原过氧化还原酶(Prx)家族的过氧化底物，揭示了其在细胞氧化应激防御中的分子机制。
---
2. **标题**: *"Structural and functional characterization of sulfiredoxin homologs from pathogenic bacteria"*
**作者**: Park AK, Kim HJ, Kim YJ, et al.
**摘要**: 本研究对比了多种病原菌来源的SRXN1同源蛋白的结构与功能。通过重组表达和晶体学分析，发现细菌SRXN1在催化机制上与人类SRXN1存在差异，为开发针对细菌抗氧化系统的抗菌药物提供了理论依据。
---
3. **标题**: *"SRXN1 overexpression mitigates doxorubicin-induced cardiotoxicity via Nrf2 signaling pathway"*
**作者**: Li Y, Zhang C, Wang X, et al.
**摘要**: 研究团队通过重组腺病毒载体在心肌细胞中过表达SRXN1蛋白，发现其通过激活Nrf2通路显著降低阿霉素诱导的心脏毒性，表明重组SRXN1在心脏保护治疗中的潜在应用价值。
---
这些文献涵盖了SRXN1重组蛋白的制备、结构功能分析及疾病治疗应用，可作为相关研究的参考基础。如需具体期刊信息或更多文献，可进一步检索PubMed或Web of Science数据库。
**Background of SRXN1 Recombinant Protein**
Sulfiredoxin-1 (SRXN1) is a conserved antioxidant enzyme critical for maintaining cellular redox homeostasis. It plays a pivotal role in reducing hyperoxidized peroxiredoxins (Prxs), a family of peroxidases that scavenge reactive oxygen species (ROS). During oxidative stress, Prxs can become inactivated through overoxidation of their catalytic cysteine residues. SRXN1 specifically catalyzes the ATP-dependent reduction of these sulfinic acid groups (-SO2H) on Prxs, restoring their enzymatic activity and bolstering cellular defense against oxidative damage.
The gene encoding SRXN1 is regulated by the Nrf2-Keap1 pathway, a master regulator of antioxidant responses. Its expression is upregulated under oxidative or electrophilic stress, positioning SRXN1 as a key mediator in adaptive cytoprotection. Dysregulation of SRXN1 has been implicated in various pathologies, including cancer, neurodegenerative diseases, and inflammatory conditions, highlighting its dual role as a tumor suppressor or promoter depending on context.
Recombinant SRXN1 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) for functional studies. It serves as a tool to investigate redox signaling mechanisms, screen antioxidant therapeutics, or model disease-associated oxidative stress. Studies using recombinant SRXN1 have demonstrated its ability to protect cells against ROS-induced apoptosis and mitigate tissue injury in preclinical models. Additionally, structural analyses of the recombinant protein have elucidated substrate-binding domains and catalytic residues, advancing drug design targeting redox imbalance.
In summary, SRXN1 recombinant protein is essential for dissecting the molecular interplay between oxidative stress and disease, offering potential applications in biomedical research and therapeutic development.
×
